Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.89 |
| ▸ | CA1 | P00915 | 19/20 | 0.89 |
| ▸ | CA9 | Q16790 | 15/20 | 0.89 |
| ▸ | CA12 | O43570 | 12/20 | 0.89 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.89 |
| ▸ | CA4 | P22748 | 6/20 | 0.65 |
| ▸ | CA7 | P43166 | 7/20 | 0.62 |
| ▸ | CA5A | P35218 | 4/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.62 |
| ▸ | CA6 | P23280 | 2/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309694 | 0.91 | CA2 (0.73) | CA2CA1CA9CA12CA14 | |
| Sulfamide SCHEMBL5585371 | 0.89 | CA2 (0.70) | CA2CA1CA9CA12CA14 | |
| SCHEMBL1700677 | 0.87 | CA2 (0.76) | CA2CA1CA9CA12CA14 | |
| SCHEMBL22233466 | 0.82 | CA1 (0.62) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27901606 | 0.82 | CA1 (0.62) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27816697 | 0.81 | CA2 (0.75) | CA2CA1CA9CA12CA14 | |
| SCHEMBL14937572 | 0.80 | CA1 (0.63) | CA2CA1CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL11870525 | 0.80 | CA2 (0.60) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27959272 | 0.79 | CA2 (0.59) | CA2CA1CA9CA12CA14 | |
| SCHEMBL23202943 | 0.79 | CA1 (1.00) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367649-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2025-12-04 | — | — | US | disclosed |
| CN-109369506-B | Method for selectively N-methylating secondary amide | 广东石油化工学院 | 2022-05-31 | — | — | CN | disclosed |
| CN-1854128-B | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY | 2012-05-16 | — | — | CN | disclosed |
| WO-2008076778-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| CN-1264365-A | 3-benzoylindole derivatives and drugs containing the same | ZERIA PHARM CO LTD (JP) | 2000-08-23 | — | — | CN | disclosed |
| EP-0260833-A2 | Process for producing polyamide acid having siloxane bonds and polyimide having siloxane bonds and isoindoloquinazolinedione rings | HITACHI CHEMICAL COMPANY (JP) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367649-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | PPOX, AOX1, CYP3A7 | CA2 1987/4885CA1 1091/4885CA9 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.